180 related articles for article (PubMed ID: 10487526)
1. Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.
Khélifa T; Beck WT
Biochem Pharmacol; 1999 Oct; 58(8):1247-57. PubMed ID: 10487526
[TBL] [Abstract][Full Text] [Related]
2. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
Khélifa T; Beck WT
Mol Pharmacol; 1999 Mar; 55(3):548-56. PubMed ID: 10051540
[TBL] [Abstract][Full Text] [Related]
3. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
4. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
5. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
6. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
7. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis.
Seimiya H; Mashima T; Toho M; Tsuruo T
J Biol Chem; 1997 Feb; 272(7):4631-6. PubMed ID: 9020192
[TBL] [Abstract][Full Text] [Related]
8. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
10. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin.
Assefa Z; Vantieghem A; Declercq W; Vandenabeele P; Vandenheede JR; Merlevede W; de Witte P; Agostinis P
J Biol Chem; 1999 Mar; 274(13):8788-96. PubMed ID: 10085120
[TBL] [Abstract][Full Text] [Related]
11. Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
Morgan SE; Beck WT
Mol Pharmacol; 2001 Feb; 59(2):203-11. PubMed ID: 11160854
[TBL] [Abstract][Full Text] [Related]
12. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
13. Regulation of c-Jun NH2-terminal kinases in isolated canine gastric parietal cells.
Nagahara A; Wang L; Del Valle J; Todisco A
Am J Physiol; 1998 Oct; 275(4):G740-8. PubMed ID: 9756505
[TBL] [Abstract][Full Text] [Related]
14. Jun and JNK kinase are activated in thymocytes in response to VM26 and radiation but not glucocorticoids.
Testolin L; Carson C; Wang Y; Walker PR; Armato U; Sikorska M
Exp Cell Res; 1997 Feb; 230(2):220-32. PubMed ID: 9024781
[TBL] [Abstract][Full Text] [Related]
15. Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils.
Zhang JP; Wong CK; Lam CW
Clin Exp Immunol; 2000 Oct; 122(1):20-7. PubMed ID: 11012613
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis and activation of interleukin 1beta-converting enzyme/Ced-3 protease (caspase-3) and c-Jun NH2-terminal kinase 1 by benzo(a)pyrene.
Lei W; Yu R; Mandlekar S; Kong AN
Cancer Res; 1998 May; 58(10):2102-6. PubMed ID: 9605752
[TBL] [Abstract][Full Text] [Related]
18. Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH(2)-terminal protein kinase-related cell death pathway.
Bae MA; Pie JE; Song BJ
Mol Pharmacol; 2001 Oct; 60(4):847-56. PubMed ID: 11562448
[TBL] [Abstract][Full Text] [Related]
19. Activation of c-Jun N-terminal kinase 1 and caspase 3 in the tamoxifen-induced apoptosis of rat glioma cells.
Tseng SH; Wang CH; Lin SM; Chen CK; Huang HY; Chen Y
J Cancer Res Clin Oncol; 2004 May; 130(5):285-93. PubMed ID: 14997384
[TBL] [Abstract][Full Text] [Related]
20. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Mandlekar S; Yu R; Tan TH; Kong AN
Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
